ACHV → $13.63 by Jun 16, 2027.

Achieve Life Sciences \[ACHV\] has developed the first drug to treat nicotine dependence in a generation, and results of their Phase 3 trials indicate a major competitive advantage over existing options. They are also the first company to run clinical trials for vaping cessation, with initial results showing promise as well. There are currently around 49.2 million nicotine-addicted adults in the United States alone. Roughly half of these individuals make at least one attempt to quit each year. Nearly half …